Zacks Investment Research lowered shares of Protagonist Therapeutics Inc (NASDAQ:PTGX) from a hold rating to a sell rating in a research note issued to investors on Thursday morning.

According to Zacks, “Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company’s initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn’s disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States. “

A number of other equities research analysts have also recently issued reports on PTGX. Barclays PLC initiated coverage on shares of Protagonist Therapeutics in a report on Tuesday, September 6th. They issued an overweight rating and a $18.00 price objective for the company. Leerink Swann initiated coverage on shares of Protagonist Therapeutics in a research report on Tuesday, September 6th. They set an outperform rating and a $17.00 price objective for the company. Finally, BMO Capital Markets initiated coverage on shares of Protagonist Therapeutics in a research report on Tuesday, September 6th. They set an outperform rating for the company.

Shares of Protagonist Therapeutics (NASDAQ:PTGX) opened at 25.12 on Thursday. The stock’s market capitalization is $419.86 million. The stock’s 50 day moving average price is $21.82 and its 200-day moving average price is $17.93. Protagonist Therapeutics has a 12 month low of $10.02 and a 12 month high of $25.50.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.29. During the same quarter last year, the firm posted ($12.79) EPS.

Large investors have recently bought and sold shares of the company. Credit Suisse AG purchased a new stake in Protagonist Therapeutics during the third quarter valued at $358,000. BVF Inc. IL purchased a new stake in Protagonist Therapeutics during the third quarter valued at $7,924,000. RA Capital Management LLC purchased a new stake in Protagonist Therapeutics during the third quarter valued at $15,941,000. Adage Capital Partners GP L.L.C. purchased a new stake in Protagonist Therapeutics during the third quarter valued at $33,408,000. Finally, Spark Investment Management LLC purchased a new stake in Protagonist Therapeutics during the third quarter valued at $889,000.

ILLEGAL ACTIVITY WARNING: “Protagonist Therapeutics Inc (PTGX) Downgraded by Zacks Investment Research to “Sell”” was reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/25/protagonist-therapeutics-inc-ptgx-downgraded-by-zacks-investment-research-to-sell.html.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (Protagonist) is a clinical-stage biopharmaceutical company. The Company has a technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) to address unmet medical needs. Protagonist’s primary focus is on developing oral peptide drugs that specifically target biological pathways.

5 Day Chart for NASDAQ:PTGX

Receive News & Stock Ratings for Protagonist Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc and related stocks with our FREE daily email newsletter.